Pharmaceuticals

Rising Diabetes Prevalence Fuels Growth Of The Market Due To Increasing Obesity Rates And Demand For Hormone-Mimicking Therapies Is Supporting Development Across The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

May 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market During The 2026–2030 Period?

The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market size has shown strong growth in recent years. It is projected to expand from $2.89 billion in 2025 to $3.1 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. The historical increase can be attributed to a limited number of specialized peptide API manufacturers, a rising demand for peptide therapeutics, the reliance on in-house synthesis by pharmaceutical companies, regulatory compliance requirements, and an increase in preclinical and clinical trials.

The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market is poised for significant expansion over the next few years. It is forecast to grow to $4.11 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 7.3%. This expansion during the projection period can be attributed to several factors: the enhancement of contract manufacturing organization (CMO) capabilities for peptide API, increasing investments in cutting-edge peptide synthesis technologies, the progression of personalized medicine and biologics, a greater reliance on outsourcing by small and mid-size pharmaceutical companies, and the adoption of digital manufacturing and AI-based process optimization. Prominent trends anticipated within this forecast period include a growing demand for contract manufacturing of peptide APIs, an intensified focus on GMP-grade production and regulatory compliance, an increase in outsourced peptide synthesis for clinical trials, the broadening of process optimization and technology transfer services, and the implementation of custom peptide synthesis for personalized therapeutics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25870&type=smp

What Primary Factors Are Fueling The Expansion Of The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?

The increasing incidence of diabetes is projected to fuel the expansion of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market moving forward. Diabetes is defined as a chronic metabolic condition characterized by elevated blood sugar (glucose) levels, resulting from the body’s insufficient insulin production or its inability to use insulin effectively. The growing occurrence of diabetes is primarily driven by rising obesity rates, as excessive body fat contributes to insulin resistance and disrupts blood sugar control. Peptide therapeutics utilize contract API manufacturing to facilitate the large-scale production of hormone-mimicking drugs, thereby enhancing insulin secretion and glucose management in diabetes treatment. For example, in March 2025, a report issued by the Office for Health Improvement and Disparities, a UK-based government department, revealed that the documented prevalence of type 2 diabetes among adults aged 17 and over in England was 7.0% as of March 2024, representing an increase from 6.8% in March 2023. Thus, the escalating prevalence of diabetes is stimulating the growth of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market.

What Are The Major Segment Categories Within The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?

The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market covered in this report is segmented –

1) By Scale Of Operation: Preclinical Or Clinical, Commercial

2) By Synthesis Method: Non Chemical Synthesis, Chemical Synthesis

3) By Enterprise Type: Large Enterprise, Small And Medium Enterprises

Subsegments:

1) By Preclinical Or Clinical: Discovery And Preclinical Development, Phase II Or III Manufacturing, Phase I Manufacturing

2) By Commercial: Commercial-Scale Good Manufacturing Practice Manufacturing, Tech Transfer And Scale-up, Lifecycle Management Or Process Optimization

What Trends Are Affecting The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Dynamics?

Companies prominent in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market are concentrating on developing innovative methods, such as the continuous flow synthesis platform, to streamline production and address the rising complexity in drug development. This continuous flow synthesis platform integrates multiple stages, including reaction, separation, concentration, and crystallization, into one unbroken process with real-time in-line measurement, thereby enabling high-precision, non-destructive monitoring and effective scale-up. For example, in May 2023, SynCrest Inc., a Japan-based contract research, development, and manufacturing organization (CRDMO), declared the opening of its good manufacturing practice (GMP)-compliant Naruto Plant, which is outfitted with a continuous flow synthesis platform for peptide and nucleotide API production. The platform supports the swift and high-quality manufacturing of over 100 types of non-natural amino acids and high-purity special amidites, substantially cutting down lead times and production costs. This innovation is satisfying the escalating market demand for advanced peptide-based therapeutics by providing scalable, efficient, and cost-effective API manufacturing solutions.

Who Are The Leading Firms Participating In The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?

Major companies operating in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market are Thermo Fisher Scientific Inc., Lonza Group AG., WuXi AppTec Co. Ltd., Cambrex Corporation, ChemPartner, GenScript Biotech Corporation, Bachem Group, CordenPharma International GmbH, Syngene International Limited, Ambiopharm Inc., CPC Scientific Inc., ScinoPharm Taiwan Ltd., Hybio Pharmaceutical Co. Ltd., CSBio Company Inc., Senn Chemicals AG., AnaSpec Inc., LifeTein LLC, Apex Biotechnology Corp., BCN Peptides S.A.

Access The Complete Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Report:

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-contract-active-pharmaceutical-ingredient-api-manufacturing-global-market-report

Which Geographic Region Represents The Largest Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Share?

North America was the largest region in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=25870&type=smp

Browse Through More Reports Similar to the Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market 2026, By The Business Research Company

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Peptide Synthesis Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-synthesis-global-market-report

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-active-pharmaceutical-ingredients-manufacturing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info